In 
Clozapine is an atypical antipsychotic with superior efficacy in severely ill, treatment-resistant schizophrenics. It is a noncataleptogcnic agent (Coward et al.. 1990) with high affinity for D, and D t receptors (Van Tol ct al.. 1991) . besides having action on 5TH, (Altar et al.. I98N) and 5TH". sites (Canton et al.. 1990) .
Its efficacy in schizophrenia was clearly demonstrated in earlier studies (Elbolm & Haggcrstrom. 1974; Singer <t Law. 1974; lusliclier Cornelsscn <fc Fcrner. 1976) . but it was withdrawn from the market following reports of associated agranulocytosis (Idanpana-Hcikkle ct al.. 1977) . a potentially lifethreatening side-effect.
II was net until late eighties, that Kane et al. (1988) demonstrated the usefulness of clozapine in severely ill treatment resistant schizophrenics. This led to rejuvenation of inter, -u in the drug, and many studies, both of controlled iPickarct al.. 1992): and descriptive type (Melt/er et al.. 1990 . Davies et al.. 1991 were published. These studies gave clozapine a solid standing in the treatment of schizophrenic patients who were resistant to conventional neuroleptics.
With clozapine being prescribed more frc quently. although not regularly to even schizophrenic patient, further issues opened up. One such point of debate was its ability to ameliorate negative symptoms. The drug was seen to have an unequivocal effective resoponse on positive symptoms, and some studies also reported improvement in the negative symptoms. But what was not clear in these studies was that whether it were the primary or secondary negative symptoms that responded. As these studies also reported diminution in positive and extrapyramidal symptoms, this possibh could have led to a secondary improvement in the negative s>niptoms. rather than being a direct action of the drug. Addressing this issue. Brier ct al (1994) in a double blind study of clozapine and haloperidol concluded that the former drug was comparatively superior in treating negative symptom, although this effect was relatively minor. However, as haloperidol itself is known to have propensity for producing extrapyramidal symptoms, this conclusion docs not seem to be very convincing. Other studies that support its efficacy in ameliorating the negative s> mploins have also been published (Mclt/cr ct al.. 19X9; Picker et al.. 1992; Clozapine Study Group. 1993 . Miller et al.. 1994 while oihers have refuted this finding (Brier eta).. 1994; Conlcyetal.. 1994) . Carpenter et al. (1995) *' are profoundly con.nutted to the idea that the deficit ^tatc is enduring and that no treatment yet available can provide effective relief." (cited in Mcltzer. I'95).
Thus the present study was undertaken to evaluate the efficacy of clozapine in an open trial in schizophrenic patients who were non-responsive to the classical antipsychotics.
MATERIAL AND METHOD
In an open, non-comparative and non-crossover study schizophrenics were taken up for a 16 week trial. The cases sclectecd were either chronic schizophrenics, acutely relapsed schizophrenics, or chronic schizophrenics with exacerbation. The diagnosis of schizophrenia was made according to ICD-10 (WHO. 1992) . All the patients had already been treated in vain with at least two neuroleptics chosen from chlorpromazinc (1000 mg/day or more), halopcridol or trifluoperazine in dose equivalents of 1000 mg/day or more of chlorpromazinc. These drugs had already been tried for a period of at least six weeks in the past.
All the patients were rated on the following instruments by one of the authors (MS) 1. Brief Psychiatric Rating Scale (BPRS) (Overall & Gorham. 1962 ) at weeks 0,9. and 16.
2. Positive and Negative Syndrome Scale (PANSS) (Kay ct al.. 1988) at weeks 0.9. and 16.
3. Global Impression Scale at the beginning and end of the trial.
4. Side-effects scale-weekly.
5. Blood cell counts (Hb, TLC. DLC) -once weekly during the trial period and until 4 weeks later.
6. Blood pressure, pulse and temperature were recorded at weekly intervals.
All the patients were given a washout period of one week who were on oral neuroleptics, and four weeks for depot preparations. The patients who were not receiving any neuroleptics at the time of intake in the trial were initiated on clozapine right away after baseline investigations were completed. The initial dose was 50 mg/day which was increased to 100 mg/day by the end of the first week. Increments were made in the dose as 100 mg/week to achieve a daily dose of 300 mg by the end of the fourth week. From fifth to sixteenth week the dose range was 300-450 mg/day depending upon the therapeutic response and/or the presence of side effects.
The permitted concomitant medication was oral trihexyphenidyl for extrapyramidal symptoms, and nitrazepam for sleep.
Baseline investigations comprised of SGOT. SGPT, ECG, serum creatinine, chest X-ra\. complete nomogram and urine analysis.
A total leucocyte count below 3500/cmm or granulocyte count below 1500/cmm warranted cassation of clozapine therapy.
The total scores of BPRS and subscales of PANSS were compared at 9 and 16 weeks from the baseline. Paired Y test was employed to compare these ratings. The side-effect scores were calculated as the total percentage of patients exhibiting them.
RESULTS
A total of 29 patients, between the ages 18-40 years, were included in the study, of which 4 dropped out for various reasons (seizures -1. GIT disturbance -1. pyrexia -1 and intercurrent illness-1). Thus 25 patients (18 males and 7 females) completed the study. The mean age of the patients and the duration of illness were 28.8±5.2 years and 7.3±4.2 years respectively. The BPRS scores (Tabic 1), when compared from week 0 (40.8±12.5) showed improvement both at week 9 (27.7±7.7)and week 16 (23.2±5 1). which was highly significant statistically.
TABLE 1

BPRS TOTAL SCORES
The improvement on BPRS total scores is further illustrated by the observation that by the end of 9th week, of the 25 patients. 17(68%) had shown improvement upto 25%. By the end of trial i.e. 16 weeks, the number had changed to 19(76%) in the 26-50% group and 6(24%) in the 0-25% group. None 
(76%)
Nil of the patients had improved beyond 50% as compared to the baseline (Table2).
The PANSS scores also showed similar improvement, but the results were more variegated. When compared from the baseline, at week 9 the scores for the positive and negative syndromes, and general psychopathology showed moderately significant improvement (p<05) ( 10 (40) 4 (16) 10 (40) 4 (16) 1 (4) 17 (68) 1 (4) 3 ( 2 (8) 12 (48) 1 (4) 1 (4) 12 (48) 1 (4) 5 (20) 1 (4) 2 ( anergia, thought disturbance and paranoid/belligerence showed highly significant improvement (p<.001) ( Table 4) ; for the rest of the subscales, the scores were significant at p<.01 level.
At week 16, the trend for improvement on PANSS continued, but with little variation. Compared to that at week 9, for the positive syndrome, negative syndrome, general psychopathology, anergia, thought disturbance and paranoid/belligerence the improvement was similar, but that in activation was much more (p<.01), and for depression much less (p<.05), as compared to the other variables.
The side-effect profile (Table 5) shows that the most frequently observed side-effect was tachycardia throughout the period of the trial (68% at week 1. 48% at week 9. and 60% at week 16). followed by mild hvpersalivation (40%, 48% and 28% rcspectivly). Although a general trend seen was in diminution in the frequency of the observed sideeffects, but sedation (mild) showed an acclivity with the progression of the trial. Moderate sedation was maximally observed in the initial week, and severe sedation, although present initially in only a few patients (16% at week 1), gradually diminished in frequency (8% and 4% at weeks 9 and 16 respectively).
A significant finding was that among the 4 dropouts, none were due to hematological side-effect.
DISCUSSION
Ours was an open study in which the efficacy of clozapine was evaluated in patients of schizophrenia who had been labeled previously as chronic/resistant or were intolerant to conventional neuroleptics.
In our study the initial BPRS scores were quite high, and showed a steady diminution over the duration of the trial. The improvement rated between weeks 9 and 16 was much more than that in the initial nine weeks. However, as the trial was terminated at this point, it cannot be commented whether this improvement would have accrued further or achieved a plateau. Other studies of longer duration have reported that the benefits stablize in about 3-6 months time, after which no further benefit is seen (Lindstrom. 1988 : Melt/.er. 1992 : BrieretaL 1993 . However, this lime course of improvement seems not unique to clozapine, as Carpenter and colleagues (1995) have commented that a similar response time course is seen with the standard neuroleptic treatment.
In our study, clozapine was found to be effective against positive and negative symptoms both, as measured on PANSS. The changes in the negative symptoms, when compared from the baseline, were highly significant (Table 4) , and the patients showed benefit on all the parameters. Other workers have shown a differential response on negative symptoms.
While Kane et al. (1988) found that clozapine significantly reduced scores for emotional withdrawal, blunted affect and psychomotor retardation, Meltzer ct al. (1989) have reported that affective flattening and anhedonia does not respond to the drug. It has also been shown in some studies that the primary negative symptoms do not respond to clozapine (Conley et al.. 1994) , but the drug is only of use in ameliorating the secondary negative symptoms. Brier et al. (1994) in a controlled study, found that the patients with primary negative symptoms responded poorly to clozapine, although it was beneficial in patients with non-deficit schizophrenia. In our study we did not differentiate between deficit and non-deficit schizophrenia, neither covariated the significance of response in negative symptoms to the positive symptoms.
Clozapine, initially introduced about 3 decades ago, was withdrawn from the market owing to reports of agranuocytosis induced by it. Licberman et al. (1988) have cited a 2% cumulative incidence after 52 weeks of clozapine treatment for agranulocytosis. In our study none of the patients developed even leucopenia sufficient enough to stop the treatment.
The other common side-effects observed in our study were sedation, hypersalivation. tachycardia, postural hypotension and dizziness (Table 5) . Fitton & Heel (1990) have observed similar side-effects in as many as 40% of their of their patients. Brier at al. (1994) also found excessive salivation and tachycardia to be most frequently observed adverse effect, which is in close agreement with our findings.
This being one of the first studies in the country, we do not have other data to compare our findings with the patients in this country. This initial study has shown the benefits of clozapine in chronic or treatment-resistant patients which argues favorably for the drug. As it is a new drug for this country, and consequently, there not being much clinical experience with it, the clinicians should be cautious in using it.
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